ArticleScientific reports2025
Performance of non-laboratory Framingham risk scores using self-reported data for remote cardiovascular risk assessment.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Traditional cardiovascular disease (CVD) risk scores, such as the Framingham Risk Score (FRS), rely on laboratory and clinical measurements often unavailable in large-scale remote health surveys. Validated tools using self-reported data could expand the feasibility of risk stratification in resource-limited settings. To assess the discriminatory capacity and agreement of adapted FRS models using only self-reported data, compared to the original FRS based on clinical and laboratory inputs. This cross-sectional study used data from 6,966 Brazilian adults aged 30-74 years from the 2013 National Health Survey. Three FRS models without laboratory inputs were evaluated: FRS-BMI (with measured BMI), FRS-BMI-HwT (using self-reported BMI and hypertension diagnosis with treatment data), and FRS-BMI-HnT (using self-reported BMI and hypertension diagnosis without treatment data). The original FRS served as the reference method. Concordance was assessed for CVD-risk ≥ 5%, ≥ 10%, and ≥ 20% using Receiver Operating Characteristic (ROC) curves and a suite of statistical measures for reliability and agreement [Intraclass Correlation Coefficient (ICC), Bland-Altman, Cohen's Kappa]. Optimal cutoffs were identified by maximizing Youden's index, with stability assessed through bootstrap validation. Additional continuous accuracy metrics were computed, including Brier Score, Mean Absolute Error (MAE), Root Mean Square Error (RMSE), and Integrated Discrimination Improvement (IDI). Prevalence of CVD-risk ≥ 5%, ≥ 10%, and ≥ 20% by FRS-Original was 55.4%, 35.9%, and 20.4%, respectively. FRS-BMI achieved the highest AUCs (0.90, 0.88, 0.83), followed by FRS-BMI-HwT and FRS-BMI-HnT (0.86-0.83 and 0.86-0.78). Concordance was substantial for CVD-risk ≥ 5% and 10% (kappa > 0.70) and moderate for ≥ 20% (kappa > 0.55). All models demonstrated excellent predictive accuracy (Brier Score < 0.01) with minimal IDI values (-0.0014 to 0.0056), indicating nearly identical discrimination between adapted and original models. Bootstrap validation confirmed excellent stability of optimal thresholds (bias < 0.02). The adapted models slightly underestimated risk (mean score difference: -0.36 to -0.61). Regression models showed consistent associations with key risk factors across all versions. Self-reported FRS models demonstrated strong discriminatory capacity and high agreement with the original FRS, supporting their use in telephone and online surveys where laboratory data are unavailable. These pragmatic tools offer reliable alternatives for CVD-risk stratification in remote, low-resource, or large-scale epidemiological research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.